By expenditures
| Name | Title | Type |
|---|---|---|
| Scott Gold | Partner | Auditee |
| Brady Dutton | Chief Financial Officer | Auditee |
| Scott Gold | Partner | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 380589 | 2024 | 2026-01-09 | FORVIS MAZARS LLP | $1.89M |
| 352374 | 2023 | 2025-04-01 | Forvis Mazars LLP | $1.66M |
| 20886 | 2022 | 2023-08-27 | Forvis LLP | $1.92M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 380589 | 2024 | 2026-01-09 | 1168640 | 2024-004 | Material Weakness | Yes | N |
| 380589 | 2024 | 2026-01-09 | 1168639 | 2024-003 | Material Weakness | Yes | L |
| 380589 | 2024 | 2026-01-09 | 1168638 | 2024-004 | Material Weakness | Yes | N |
| 380589 | 2024 | 2026-01-09 | 1168637 | 2024-003 | Material Weakness | Yes | L |
| 380589 | 2024 | 2026-01-09 | 1168636 | 2024-004 | Material Weakness | Yes | N |
| 380589 | 2024 | 2026-01-09 | 1168635 | 2024-003 | Material Weakness | Yes | L |
| 352374 | 2023 | 2025-04-01 | 1130231 | 2023-004 | Significant Deficiency | - | N |
| 352374 | 2023 | 2025-04-01 | 1130230 | 2023-003 | Significant Deficiency | - | L |
| 352374 | 2023 | 2025-04-01 | 1130229 | 2023-004 | Significant Deficiency | - | N |
| 352374 | 2023 | 2025-04-01 | 1130228 | 2023-003 | Significant Deficiency | - | L |
| 352374 | 2023 | 2025-04-01 | 1130227 | 2023-004 | Significant Deficiency | - | N |
| 352374 | 2023 | 2025-04-01 | 1130226 | 2023-003 | Significant Deficiency | - | L |
| 352374 | 2023 | 2025-04-01 | 553789 | 2023-004 | Significant Deficiency | - | N |
| 352374 | 2023 | 2025-04-01 | 553788 | 2023-003 | Significant Deficiency | - | L |
| 352374 | 2023 | 2025-04-01 | 553787 | 2023-004 | Significant Deficiency | - | N |
| 352374 | 2023 | 2025-04-01 | 553786 | 2023-003 | Significant Deficiency | - | L |
| 352374 | 2023 | 2025-04-01 | 553785 | 2023-004 | Significant Deficiency | - | N |
| 352374 | 2023 | 2025-04-01 | 553784 | 2023-003 | Significant Deficiency | - | L |